uniQure N.V. (QURE) NASDAQ

13.68

-1.3(-8.68%)

Updated at July 29 04:00PM

Currency In USD

uniQure N.V.

Address

Paasheuvelweg 25a

Amsterdam, 1105 BP

Netherlands

Phone

31 20 240 6000

Sector

Healthcare

Industry

Biotechnology

Employees

209

First IPO Date

February 05, 2014

Key Executives

NameTitlePayYear Born
Mr. Matthew Craig Kapusta CPAChief Executive Officer & Executive Director1.13M1972
Mr. Christian KlemtChief Financial Officer, Principal Financial Officer & GM of Amsterdam Site679,7931973
Mr. Richard Porter Ph.D.Chief Business & Scientific Officer732,1691968
Dr. Jeannette Potts J.D., Ph.D.Chief Legal & Compliance Officer and Corporate Secretary738,5471962
Dr. Walid Abi-Saab M.D.Chief Medical Officer946,1321965
Ms. Erin BoyerChief People & Culture Officer0N/A
Prof. Hugo KatusChairman of Scientific Advisory Board and Managing Director of UniQure-Germany0N/A
Dr. Amin Abujoub Ph.D.Chief Technical Operations Officer0N/A
Dr. Tamara Tugal Ph.D., MBABusiness Development Director0N/A
Eileen SawyerVice President of Global Medical Affairs0N/A

Description

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.